Eli Lilly Expands Oncology Pipeline with $2.3 Billion Acquisition of Ajax Therapeutics

Eli Lilly and Company (LLY) announced on Monday its acquisition of Ajax Therapeutics, Inc., a move designed to accelerate the development of AJ1-11095. The asset is an investigational, once-daily oral Type II JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis. The acquisition strengthens Lilly's oncology portfolio by integrating a first-in-class therapy aimed at providing deeper and more durable efficacy than current market options. According to company leadership, the therapy's tolerability profile is expected to allow patients to remain on treatment longer, making it a viable candidate for both first- and second-line settings. Under the terms of the agreement, Ajax shareholders are eligible to receive up to $2.3 billion in total cash. This valuation comprises an initial upfront payment followed by subsequent payments contingent upon the achievement of specific clinical and regulatory milestones. Eli Lilly, which previously served as a founding strategic investor in Ajax, saw its shares trade slightly higher in pre-market activity at $884.65. The move signals a continued aggressive expansion into specialized cancer treatments and the integration of high-potential biotech assets into its broader corporate strategy.